No Data
Oppenheimer Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $20
Terns Pharmaceuticals Reports 2024 Progress and Outlook
Terns Pharmaceuticals: Promising Investment With Strong Financials and Strategic Developments
$TERN Stock Is up 10% Today. Here's What We See in Our Data.
Express News | Terns Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q4 Financial Results
William Blair Reaffirms Their Hold Rating on Terns Pharmaceuticals (TERN)
iluvpoptarts : ty much. I owe you a good joke when you're ready
justinsica97 : when will CCTG pump occur? pre market today?
Jaguar8 OP justinsica97 : it already started pumping Friday AH
justinsica97 Jaguar8 OP : is it too late if i pump today during pre market sir?
Arrayfunction : This is probably an unknowable question - but logically, the massive cuts at NIH and NSF are going to stall out the biotech industry with what.....an 8-10 year lag? I know they don't tend to fund private clinical trials all that often, but they are shutting the tap off at the academic institutions that come up with the molecules that biotech/pharma buys the rights to?
View more comments...